Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates

Stéphane Pillet(McGill University Health Centre), Brian J. Ward(McGill University Health Centre)

Cellular and Molecular Immunology

January 4, 2022

10.1038/s41423-021-00809-2

Cited by 59

Related Papers

Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages

|npj Vaccines|2019|42

Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity

|npj Vaccines|2022|16

Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03

|medRxiv|2022|7